Anti Cd 20 Ocrevus denied for missing prior authorization by Blue Cross Blue Shield?

Blue Cross Blue Shield's specific coverage criteria for anti cd20 ocrevus are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why BCBS Requires Prior Authorization for Ocrelizumab

As a high-cost specialty biologic, ocrelizumab (Ocrevus) is subject to prior authorization (PA) on virtually all BCBS plans. A PA-required denial typically means either that no authorization was obtained before the infusion or prescription was processed, or that an authorization request was submitted but denied because the documentation did not satisfy BCBS's coverage criteria. Understanding which situation applies shapes the appeal strategy.

## Why This Denial Is Appealable

When a PA request is denied on clinical grounds, it is an adverse benefit determination subject to your full appeal rights. Under ACA §2719 and ERISA §503, you are entitled to a full-and-fair internal appeal and, if that is upheld, independent external review by a certified IRO. The external-review filing window is generally around four months from the adverse determination; verify the precise deadline in your Summary Plan Description. An expedited review (usually 72 hours) is available when the standard timeline would seriously jeopardize health — which is highly relevant for a patient whose MS may be actively progressing.

## Your Appeal Timeline

1. Request the denial letter and BCBS's PA criteria — the insurer must provide the specific criteria used to evaluate the request. 2. Identify the gap: compare the submitted documentation against the criteria and determine exactly what was missing or insufficient. 3. File the internal appeal within the deadline stated in the denial letter (typically 180 days for internal appeals). 4. Submit supplemental clinical documentation addressing each unmet criterion. 5. Escalate to external review if the internal appeal is denied.

## Documentation to Gather

• Prescriber letter of medical necessity: the treating neurologist should document the confirmed MS diagnosis and subtype, the clinical course and severity (with chart-based evidence), all prior disease-modifying therapies tried with dates and outcomes, and the individualized rationale for selecting ocrelizumab.
• Diagnosis records: recent neurology notes, MRI reports with radiologist interpretation, and any functional or disability assessments from the chart.
• Prior-therapy documentation: chart notes, prescription records, or pharmacy records showing each previously tried MS therapy, the duration of use, the clinical response, and the reason for discontinuation.
• FDA prescribing label: confirm that the patient's MS subtype is an approved indication and that the proposed use aligns with the label.
• Applicable guideline reference: a citation to the relevant neurology guideline organization (such as the AAN) supporting ocrelizumab in this clinical context.

## Criteria-Mapping Structure

Obtain BCBS's published prior-authorization criteria for ocrelizumab and map each requirement to chart evidence:

| PA Criterion | Chart Evidence | Document & Date | |---|---|---| | Confirmed MS diagnosis and subtype | Neurology note, MRI report | [Date] | | Prior therapy trial(s) with outcomes | Treatment summary | [Date range] | | Clinical severity / disease activity | MRI findings, functional score | [Date] | | Prescriber specialty confirmation | Neurologist credentials | [Date] |

A criterion-by-criterion response eliminates ambiguity and gives the reviewer a direct path to approval. Include a table of contents so the reviewer can locate each piece of evidence immediately.